U-AGNPF

Q:AGNPF - ALGERNON PHARMACEUTICALS INC - Website unknown - click to update

04:52:17 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
AGNPF - Q	not subscribed					0.13	+0.0024	1.9	575.4	71	117	0.1289 0.13 0.1195	0.4867 0.1207	15:58:16	Apr 08	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQB -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 117

Time ET	Ex	Price	Change	Volume
15:58:16	Q	0.13	0.0024	20,000
15:57:16	Q	0.13	0.0024	800
15:52:20	Q	0.12872	0.00112	27
15:25:34	Q	0.1254	-0.0022	1,000
15:25:34	Q	0.1254	-0.0022	500
15:23:38	Q	0.124	-0.0036	3,962
15:23:33	Q	0.125385	-0.002215	1,500
15:07:51	Q	0.1256	-0.002	1,000
14:50:03	Q	0.12576	-0.00184	10,000
14:47:40	Q	0.124	-0.0036	1,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2021-04-08 07:00	U:AGNPF	News Release200	Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
2021-04-06 08:00	U:AGNPF	News Release200	Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
2021-03-31 08:00	U:AGNPF	News Release200	Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
2021-03-29 07:02	U:AGNPF	News Release200	Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

Date ET

Symbol

Type

Headline

2021-04-08 07:00

U:AGNPF

News Release

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

2021-04-06 08:00

U:AGNPF

News Release

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program